PRRT2 and Hyperglycemia: Hyperglycemia affects endotheliopathy through pathways leading to microangiopathy, such as polyol, hexosamine, advanced glycation end-products (AGEs), and protein kinase C (PKC) pathways (Figure 2) [12].